Table 1 Summary of clinical studies assessing infectious disease mRNA vaccines.
From: The promise of mRNA vaccines: a biotech and industrial perspective
Disease target | Study stage | mRNA | Delivery formulation | Trial citation | Status | Organization | Ref. |
|---|---|---|---|---|---|---|---|
RSV | Ph1 | mRNA-1172 | Merck proprietary formulation | Not known | Ongoing | Merck/Moderna | |
Rabies | Ph1 | RG-SAM [CNE] | Cationic lipid formulation | NCT04062669 | Ongoing | GSK | |
Chikungunya virus | Ph1 | mRNA-1388 | Not disclosed | Not known | Ongoing (interim results) | Moderna | |
Rabies | Ph1 | CV7202 | LNP | NCT03713086 | Ongoing (interim results) | Curevac | |
Human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3) | Ph1 | mRNA-1653 | LNP | NCT03392389 | Ongoing (interim results) | Moderna | |
Influenza (H10N8) | Ph1 | mRNA-1440 | LNP | NCT03076385 | Ongoing (interim results) | Moderna | |
Influenza (H7N9) | Ph1 | mRNA-1851 | LNP | NCT03345043 | Ongoing (interim results) | Moderna | |
Cytomegalovirus (CMV); six valencies expressing a pentamer and gB | Ph1 | mRNA-1647 mRNA-1443 | LNP | NCT03382405 | Ongoing (interim results for mRNA-1647) | Moderna | |
Zika virus | Ph1 | mRNA-1893 | LNP | NCT04064905 | Ongoing | Moderna | |
Zika virus | Ph1 | mRNA-1325 | Not disclosed | NCT03014089 | Completed | Moderna | |
Rabies virus | Ph1 | CV7201 | Protamine | NCT02241135 | Completed | Curevac | |
RSV | Ph1 | mRNA-1777 | Not disclosed | Not known | Completed (not yet reported) | Merck/Moderna |
